Loading clinical trials...
Loading clinical trials...
Phase II Randomized Study of Multiple Doses of Palonosetron Plus Aprepitant Versus Multiple Doses of Palonosetron Alone in Preventing CINV in Patients With Newly Diagnosed AML or High-risk MDS Receiving Multiple Days Chemotherapy
Conditions
Interventions
Palonosetron + Aprepitant
Palonosetron
Locations
11
Italy
Università-Azienda Policlinico di Bari
Bari, BA, Italy
Ospedale Perrino
Brindisi, BR, Italy
Ospedale Pugliese-Ciacco
Catanzaro, CZ, Italy
IRCCS Casa Sollievo della Sofferenza
San Giovanni Rotondo, FG, Italy
Ospedale Vito Fazzi
Lecce, LE, Italy
Ospedale "Cardinale Panico"
Tricase, LE, Italy
Start Date
October 1, 2011
Primary Completion Date
August 1, 2014
Completion Date
October 1, 2014
Last Updated
July 31, 2014
NCT01596413
NCT01362530
NCT02097823
Lead Sponsor
Associazione Salentina Angela Serra
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions